TransEnterix (NYSEAMERICAN:TRXC) Shares Gap Down to $0.27

Share on StockTwits

TransEnterix, Inc. (NYSEAMERICAN:TRXC)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $0.28, but opened at $0.27. TransEnterix shares last traded at $0.26, with a volume of 38,982 shares traded.

A number of equities research analysts have issued reports on the stock. Royal Bank of Canada lowered shares of TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price target on the stock. in a report on Thursday, August 8th. Zacks Investment Research lowered shares of TransEnterix from a “hold” rating to a “sell” rating in a report on Thursday, October 10th.

TransEnterix (NYSEAMERICAN:TRXC) last announced its quarterly earnings results on Tuesday, November 12th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The business had revenue of $2.02 million for the quarter, compared to analyst estimates of $4.68 million.

Several institutional investors and hedge funds have recently made changes to their positions in the company. First Trust Advisors LP boosted its stake in shares of TransEnterix by 89.1% during the 3rd quarter. First Trust Advisors LP now owns 1,336,607 shares of the medical instruments supplier’s stock valued at $828,000 after purchasing an additional 629,658 shares in the last quarter. Prospera Financial Services Inc boosted its stake in shares of TransEnterix by 38.3% during the 3rd quarter. Prospera Financial Services Inc now owns 208,600 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 57,800 shares in the last quarter. Tradewinds Capital Management LLC boosted its stake in shares of TransEnterix by 225.2% during the 3rd quarter. Tradewinds Capital Management LLC now owns 77,400 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 53,600 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in shares of TransEnterix during the 2nd quarter valued at about $2,136,000. Finally, Morgan Stanley boosted its stake in shares of TransEnterix by 225.2% during the 2nd quarter. Morgan Stanley now owns 1,448,957 shares of the medical instruments supplier’s stock valued at $1,970,000 after purchasing an additional 1,003,339 shares in the last quarter.

About TransEnterix (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Featured Story: Certificate of Deposit (CD) For Risk Adverse Investors?

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.